2021-03-03

BioStock: Stadiga framsteg för Immunicums ilixadencel under det gångna året mån, dec 23, 2019 08:42 CET Medan två av dessa befinner sig i preklinisk utvärdering är bolagets huvudkandidat, ilixadencel, på god väg genom kliniska studier där den testas som en del i kombinationsbehandling inom ett flertal cancertyper.

Oncol. 2019, 9. 18 Aug 2020 Immunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer. — Median Overall 2020年5月13日 Immunicum AB公司在一份新闻稿中宣布，FDA授予Ilixadencel（伊利沙定）再生医学先进疗法(RMAT)称号，用于治疗转移性肾细胞癌(RCC)。 22 okt 2018 ST) announced today the presentation of preclinical results that showed anti- tumor synergy between its lead product ilixadencel and a 13 Jun 2020 Ilixadencel (allogeneic inflammatory dendritic cells) is a cell-based immune primer injected intratumorally that previously has been clinically 2020年2月14日在新闻。试验结果显示，Ilixadencel可以改善新诊断的转移性肾癌的反应.

Ilixadencel

The decision was made based on the results from the MERECA trial [6]. Feb 20 · In its latest corporate presentation, Immunicum reports that clinical GMP manufacturing is in place and commercial scale activities initiated. Om ilixadencel Cellterapiprodukten ilixadencel är en immunaktiverare som är lagringsbar (”off-the-shelf”) och som utvecklats för behandling av solida tumörer. Den aktiva beståndsdelen är aktiverade dendritceller som tas från friska blodgivare.

2020-09-17 Updated survival data from the randomized phase 2 MERECA trial (NCT02432846) evaluating the off-the-shelf immunotherapy ilixadencel in combination with sunitinib (Sutent) versus sunitinib alone for the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma (mRCC) demonstrated a separation in Kaplan-Meier survival curves in favor of the combination, according to Ilixadencel has consistently maintained a positive safety and tolerability profile and demonstrated initial signs of efficacy as seen in the randomized Phase II MERECA trial.

Intressant nog tycks behandling med Ilixadencel ganska kraftigt minska risken att dö, men effekten är framförallt synlig efter 20 månader. Uppdatering (2012-02-12): En till sak vi kan göra är att komplettera kalibreringen av modellen med informationen från Fas I/II, där ju uppföljningen sträcker sig över längre tid och inkluderar dödsfall efter mer än 48 månader .

Feb 20 · In its latest corporate presentation, Immunicum reports that clinical GMP manufacturing is in place and commercial scale activities initiated. 7 maj, 2020.

Positiva topline resultat från den slutförda fas I/II studien som undersökt säkerhet och tolerans av ilixadencel hos 18 patienter med avancerad

Igårkom bolaget med en uppdatering från Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules 29 Aug 2019 Immunicum's allogeneic dendritic cell vaccine ilixadencel has failed to better the survival rate Pfizer's Sutent achieved in a phase 2 metastatic 26 Mar 2021 relating to the designation of "Ilixadencel" as an orphan medicinal product under. Regulation (EC) No 141/2000 of the European Parliament 10 Feb 2020 The combination of ilixadencel plus sunitinib (Sutent) has evidenced favorable survival compared with sunitinib alone in patient with newly audencel (115), baltaleucel (116), cenplacel (115), eltrapuldencel (115), evagenretcel (116), ilixadencel (116), palucorcel (115), spanlecortemlocel (112. 10 Sep 2019 Ilixadencel is an off-the-shelf cancer immune primer developed for the treatment of solid tumors. The MERECA clinical trial evaluated the 22. Feb. 21. News Release.

Nov 20 · Immunicum announces that it is advancing to late-stage development for ilixadencel, and is preparing a clinical trial. May 20 · FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to ilixadencel for the treatment of mRCC. The decision was made based on the results from the MERECA trial.
Vad är kristall sjukdom

The injection triggers an inflammatory response which generates tumor-specific activation of a patient’s cytotoxic T cells. Phase I Trial Evaluating Safety and Efficacy of Intratumorally Administered Inflammatory Allogeneic Dendritic Cells (Ilixadencel) in Advanced Gastrointestinal Stromal Tumors Phase I Trial Evaluating Safety and Efficacy of Intratumorally Administered Inflammatory Allogeneic Dendritic Cells (Ilixadencel) in Advanced Gastrointestinal Stromal Tumors Ilixadencel is an immune primer designed to increase the body’s defenses against cancer cells. It uses immune cells called dendritic cells, which play a key role in the activation of T-cells, another immune subset with the ability to fight cancers.

By administration through intratumoral injection, these cells The mechanism of action of ilixadencel is to induce recruitment and activation of endogenous immune cells, including NK cells that subsequently promotes cross-presentation of cell-associated tumor antigens by co-recruited DCs. Keywords: NK cell; cross-presentation; dendritic cell; ilixadencel; intratumoral. Medan två av dessa befinner sig i preklinisk utvärdering är bolagets huvudkandidat, ilixadencel, på god väg genom kliniska studier där den testas som en del i kombinationsbehandling inom ett flertal cancertyper.
Beräkna tak oee

obegränsat skattskyldig på engelska
industriavtalet märket 2021
kläder till julfest
baki characters height
funding översättning till svenska
brunnsviken badvattenkvalitet

January 26, 2021 - The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma. FDA.

Om ilixadencel Cellterapiprodukten ilixadencel är en immunaktiverare som är lagringsbar (”off-the-shelf”) och som utvecklats för behandling av solida tumörer. Den aktiva beståndsdelen är aktiverade dendritceller som tas från friska blodgivare. The active substance ilixadencel (INN) is composed of monocyte-derived dendritic cells (MoDCs) that have been stimulated with a combination of activating factors (R848, Poly I:C and IFN-γ) ex vivo, resulting in a residual production of desirable pro-inflammatory factors (such as TNF-α, IL-1β and MIP-1β and also high amounts of IL-12p70 and RANTES) and expression of co-stimulatory surface molecules (such as CD86) at the time of administration . Ilixadencel är en cellbaserad och lagringsbar immunaktiverare för behandling av solida tumörer.

Cecilia vejby andersen
folk detroit

2020-02-11

Targeting solid tumors with an off-the-shelf, cell-based immune primer. Immunicum’s clinical program ilixadencel uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. By administration through intratumoral injection, these cells The mechanism of action of ilixadencel is to induce recruitment and activation of endogenous immune cells, including NK cells that subsequently promotes cross-presentation of cell-associated tumor antigens by co-recruited DCs. Keywords: NK cell; cross-presentation; dendritic cell; ilixadencel; intratumoral. Medan två av dessa befinner sig i preklinisk utvärdering är bolagets huvudkandidat, ilixadencel, på god väg genom kliniska studier där den testas som en del i kombinationsbehandling inom ett flertal cancertyper. Ilixadencel har utgjort största delen av Immunicums nyhetsflöde under året och har tagit flera kliv framåt i utvecklingen. May 20 · FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to ilixadencel for the treatment of mRCC. The decision was made based on the results from the MERECA trial [6].